Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience

Budamakuntla, Leelavathy; Madaiah, M.; Sarvajnamurthy, Sacchidanand; Kapanigowda, Shilpa

doi:10.1111/ced.12509

Cited by 14 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secukinumab and ustekinumab had greater efficacy compared to etanercept, as per two head-to-head studies in psoriasis. Alefacept showed sustained treatment benefit for a drug-free follow-up period of 12 weeks in patients with psoriasis (suggesting the possibility of intermittent treatment regimens), and itolizumab was associated with very prolonged drug-free remission (up to 5 years) [ 97 ].…”

Section: Discussionmentioning

confidence: 99%

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

2016

View full text Add to dashboard Cite

The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed and nonlicensed) based on their proven efficacy in treating different clinical manifestations associated with psoriasis and PsA. This review presents the level of evidence of efficacy of different biologic treatments and small molecule inhibitors for certain clinical features of treatment of PsA and psoriasis, which was graded in categories I–IV. The literature searches were performed on the following classes of biologic agents and small molecules: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), anti-IL12/IL23 (ustekinumab), anti-IL17 (secukinumab, brodalumab, ixekizumab), anti-IL6 (tocilizumab), T cell modulators (alefacept, efalizumab, abatacept, itolizumab), B cell depletion therapy (rituximab), phosphodiesterase 4 inhibitor (apremilast) and Janus kinase inhibitor (tofacitinib). A comprehensive table including 17 different biologic agents and small molecule inhibitors previously tested in psoriasis and PsA was generated, including the level of evidence of their efficacy for each of the clinical features included in our review (axial and peripheral arthritis, enthesitis, dactylitis, and nail and skin disease). We also proposed a limited set of recommendations for a sequential biologic treatment algorithm for patients with PsA who failed the first anti-TNF therapy, based on the available literature data. There is good evidence that many of the biologic treatments initially tested in psoriasis are also effective in PsA. Further research into both prognostic biomarkers and patient stratification is required to allow clinicians the possibility to make better use of the various biologic treatment options available. This review showed that there are many potentially new treatments that are not included in the current guidelines that can be used for selected categories of patients based on their disease phenotype, clinician experience and access to new biologic therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, Itolizumab efficacy for providing long-lasting remission has been previously reported in literature. [9] Elyoussfi et al . in a recent article emphasized that a number of treatment options that are not part of current guidelines can be effectively used in individualized patient settings based on the disease phenotype and clinician experience.…”

Section: Discussionmentioning

confidence: 99%

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis

Parthasaradhi

Singh²,

Parasramani³

et al. 2017

Indian Dermatol Online J

View full text Add to dashboard Cite

Background:While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse.Aims:The current study assessed the effectiveness of itolizumab in real-world settings.Materials and Methods:This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore. Registry data of 155 patients who were prescribed itolizumab at a dose of 1.6 mg/kg every 2 weeks for the first 12 weeks followed by 1.6 mg/kg every 4 weeks for up to 24 weeks for chronic plaque psoriasis.Results:In the study, 35.48% completed itolizumab for 12 weeks and 76.59% of these patients achieved PASI 75. Furthermore, 24.51% patients completed the full Itolizumab regimen for 24 weeks, of whom 92.01% patients achieved PASI 75. The mean percent change in DLQI scores at weeks 12 and 24 were 60.19 and 82.72, respectively. Adverse events and infusion reactions noted in the study were generally of mild to moderate severity.Conclusion:Itolizumab is a safe and effective option in treatment-compliant patients with chronic plaque psoriasis. Effects of putative compliance-modulators such as cost, route of administration, and delayed onset of action warrant further investigation.

show abstract

“…The safety of itolizumab was also established in a case series of five patients reported by Nott et al,13 a case series of seven patients by Singh,14 a case series of 20 patients by Parthasaradhi,15 a case series of 155 patients by Parthasaradhi et al,16 a case series of five patients by Pai and Pai,17 a case report presented by Trasi et al,18 a case report by Gupta et al,19 and a case report by Budamakuntla et al20 In all the clinical studies and individual case reports or case series, itolizumab was safe and well tolerated (Tables 2 and 3).…”

Section: Safety and Efficacy Of Itolizumab For Psoriasis In Indian Pamentioning

confidence: 94%

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Budamakuntla

Shree-Lakshmi

Bansal

et al. 2019

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

show abstract

Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience

Cited by 14 publications

References 10 publications

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Contact Info

Product

Resources

About